Brad Everson has served HepQuant since the company’s founding, leading business development efforts. He secured initial research contracts with leading institutions that led to recent publications featuring HepQuant technology in major journals. He has created and driven long-term strategic relationships with key stakeholders at pharmaceutical companies that have led to current HepQuant use in liver tests for clinical trials during drug development.
Mr. Everson has also helped create long-term relationships with potential partners, including opportunities such as Coram Clinical Trials (CCT) division of CVS Health offering remote and mobile HepQuant test administration services in clinical trials. He was a key business advisor contributing to business development and commercial plans for a proof of concept and an Advanced Industries ESCR grant award. This effort helped to secure initial post-seed investment and subsequent funding rounds. Mr. Everson has also represented HepQuant at, and spoken at, various regional and national investor and partnering conferences.
Mr. Everson’s primary responsibilities are business sales, collaborative and strategic relationships, business development and commercial planning, and management of Business Development. He possesses more than 20 years of experience in research, business and technical sales, business development, and entrepreneurship.
Mr. Everson graduated from University of Colorado at Boulder with a BA in Mathematics and Psychology, minor in Chemistry, and holds credentials from Johnson Graduate School of Management at Cornell University.